Methods of using regenerative cells in the treatment of renal diseases and disorders

• US 20050048033A1
• Filed: 07/01/2004
• Published: 03/03/2005
• Est. Priority Date: 12/07/2001
• Status: Active Grant

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H., Daniels, Eric
• Granted Patent: US 8,404,229 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2430/26 for kidney reconstruction
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61M 1/3692 Washing or rinsing blood or blood constituents
• CPC Class Codes: A61M 1/3693 using separation based on different densities of components, e.g. centrifuging
• CPC Class Codes: A61M 1/3696 with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
• CPC Class Codes: A61M 2202/0437 Blood stem cells
• CPC Class Codes: A61M 2202/08 Lipoids
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Abstract

Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.

Claims

1. A method for treating acute tubular necrosis (ATN) in a patient, comprising:

administering to the patient a concentration of regenerative cells, such that the ATN is treated.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the regenerative cells are comprised of stem cells.

4. The method of claim 1, wherein the regenerative cells are comprised of progenitor cells.

5. The method of claim 1, wherein the regenerative cells are comprised of a combination of stem cells and progenitor cells.

6. The method of claim 1, wherein the ATN is ischemic ATN.

7. The method of claim 1, wherein the ATN is nephrotoxic ATN.

8. The method of claim 1, wherein the method comprises administering a bolus of the regenerative cells.

9. The method of claim 1, wherein the method comprises administering multiple doses of the regenerative cells.

10. The method of claim 1, wherein the method further comprises administering one or more angiogenic factors.

12. The method of claim 1, wherein the wherein the method further comprises administering one or more immunosuppressive drugs.

13. The method of claim 1, wherein the regenerative cells are administered via an intravenous, intra-arterial or intra-parenchymal administration route.

14. The method of claim 1, wherein the method further comprises administering the regenerative cells to the patient'"'"'s renal vasculature.

15. The method of claim 1, wherein the regenerative cells are grown in cell culture prior to being administered to the patient.

16. The method of claim 15, wherein the regenerative cells are grown in culture conditions that promote differentiation towards a renal phenotype.

17. The method of claim 15, wherein the cell culture conditions promote differentiation towards an endothelial phenotype.

18. The method of claim 15, wherein the cell culture is performed on a scaffold material to generate a two or three dimensional construct that can be placed on or within the patient.

19. The method of claim 18, wherein the scaffold material is resorbable in vivo.

20. The method of claim 1, wherein the regenerative cells are modified by gene transfer such that expression of one or more genes in the modified regenerative cells is altered.

21. The method of claim 20, wherein the modification results in alteration of the level of angiogenesis in the subject.

22. The method of claim 20, wherein the modification results in alteration of the level of apoptosis in the subject.

23. The method of claim 20, wherein apoptosis of tubular cells is altered.

24. The method of claim 20, wherein the modification results in alteration of the homing properties of the regenerative cells.

25. The method of claim 1, wherein the administering comprises administering to the patient a composition comprising a concentration of adipose tissue derived regenerative cells, wherein the composition is administered to the same patient from which the adipose tissue was originally harvested.

26. A method for promoting tubular cell growth comprising contacting a localized area of tissue with a concentration of regenerative cells such that tubular cell growth within the area of tissue is induced.